Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) has been assigned an average recommendation of “Hold” from the fifteen analysts that are covering the stock. Two equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among […]
